The Role of 5-Phosphodiesterase Inhibitors (PDE-5I) in Current Benign Prostatic Hyperplasia Treatment: A Narrative Review
<i>Introduction</i>: 5-phosphodiesterase inhibitors (PDE-5I) have been investigated as a treatment for urinary dysfunction for almost a decade. The general perception is that they play a significant role in managing lower urinary tract symptoms (LUTS), particularly those associated with...
Saved in:
| Main Authors: | Konstantinos Stamatiou, Gianpaolo Perletti, Vittorio Magri, Alberto Trinchieri |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-10-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1648-9144/60/11/1736 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia
by: Eric H. Kim, et al.
Published: (2018-01-01) -
Testosterone and 5 Alpha Reductase Inhibitor (5ARI) in Benign Prostatic Hyperplasia (BPH): A historical perspective
by: Ananias C. Diokno, et al.
Published: (2024-12-01) -
Phosphodiesterase type 5 inhibitors and erectile dysfunction
by: Catherine Whittaker
Published: (2010-06-01) -
Does the addition of Serenoa repens to tamsulosin improve its therapeutical efficacy in benign prostatic hyperplasia?
by: Argirović Aleksandar, et al.
Published: (2013-01-01) -
Cost effectiveness comparison of dutasteride and finasteride in patients with benign prostatic hyperplasia - the Markov model based on data from Montenegro
by: Dabanović Vera, et al.
Published: (2016-01-01)